Valeant's (VRX) Buy Rating Affirmed at BofA/Merrill Lynch
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/19/2026
Go back to Valeant's (VRX) Buy Rating Affirmed at BofA/Merrill Lynch
October 22, 2015 10:45 AM EDT
Citron Research said it will be on Bloomberg TV at 12:30PM ET to discuss Valeant Pharma (NYSE: VRX) which follows yesterday's scathing report and drastic sell-off.
Bloomberg's live feed can be found here:... More
October 22, 2015 9:44 AM EDT
Valeant Pharma (NYSE: VRX) is back testing the $100 level again. Shares down 15% currently.
Today's BMO Capital downgrade, highlighted earlier, is certainly not helping.
...
More
October 22, 2015 9:37 AM EDT
Deutsche Bank maintained a Hold rating on Valeant Pharmaceuticals (NYSE: VRX) with a price target of $204. Analyst Gregg Gilbert said he remains cautious on the stock given uncertainties related to the drug pricing, its specialty pharmacy distribution model, and related government inquiries.
Gilbert explained, "VRX shares have been under significant pressure, most recently following allegations related to its specialty pharmacy distribution model. While it is difficult to predict how more conservative pricing behavior and other potential changes could affect revenue growth, we thought it would be helpful to look at... More
October 22, 2015 7:00 AM EDT
BMO Capital downgraded Valeant Pharmaceuticals (NYSE: VRX) from Outperform to Market Perform with a price target of $141.00, saying they cannot defend the specialty pharmacy structure.
Analyst Alex Arfaei commented, "Based on our understanding, ~10% of Valeants revenues come from specialty pharmacies. While other companies also use specialty pharmacies, the structure of Valeants network seems different. In... More
